AzTrials
AzTrials

Buccal InfiltrationNCT06630819

Buccal Infiltration of Different Volumes of Articaine for Extraction.

A study testing 1.8 ml of 4% Articaine and 3.6 ml of 4% Articaine in people with Buccal Infiltration and Articaine, run by Qassim University at 2 sites in Saudi Arabia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study compares the effectiveness of two different volumes of buccal infiltration of Articaine for the extraction of mandibular posterior teeth. One group receives buccal infiltration of 1.8 ml of 4% Articaine and the other group receives buccal infiltration of 3.6 ml of 4% Articaine. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Buccal Infiltration, Articaine, Anesthesia
What is being tested?
1.8 ml of 4% Articaine and 3.6 ml of 4% Articaine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
114 participants
Where
2 sitesSaudi Arabia
Study dates
24 Nov 2024to 2 May 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • All healthy patients (ASA I) or patients with mild systemic disease with no functional limitations (ASA II)
  • Patients aged ≥ 18 years of age.
  • Patients requiring extraction of mandibular posterior teeth including grossly decayed tooth, grade I mobile tooth, root stumps and indicated for therapeutic reasons.
  • Patients not allergic to the drugs or anesthetic agents used in the surgery.

Who cannot join

  • Acute infection at the extraction site.
  • Patients indicated for surgical extraction of teeth.
  • Patients already taking medications affecting pain assessment.
  • Pregnant patients.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Muhammad Atif S Agwan contact

966541651713

m.abdulsaleem@qu.edu.sa

Abdul K Azad contact

00966594914343

a.azad@qu.edu.sa

Saudi Arabia2 sites, 2 recruiting
  • Qassim University

    Buraidah, Al Qassim, 52719

    Muhammad Atif S Agwan, 966-541651713, m.abdulsaleem@qu.edu.sa

    Abdullah Ahmad A Aloyouni

    Not yet recruiting
  • College of Dentistry, Qassim University

    Buraidah, 52385

    Muhammad Atif Agwan, 00966541651713, m.abdulsaleem@qu.edu.sa

    Recruiting

Other trials in Saudi Arabia

About this study

Official title: Comparing the Effectiveness of Buccal Infiltration of Different Volumes of Articaine for Extraction of Mandibular Posterior Teeth- A Randomized Clinical Trial.

This study compares the effectiveness of two different volumes of buccal infiltration of Articaine for the extraction of mandibular posterior teeth. One group receives buccal infiltration of 1.8 ml of 4% Articaine and the other group receives buccal infiltration of 3.6 ml of 4% Articaine.

Read the detailed description

The most widely and commonly used injection method for the extraction of mandibular posterior teeth is the inferior alveolar nerve block (IANB) technique. However, various complications like pain during injection, transient facial nerve paralysis, trismus, hematoma, and paresthesia are associated with the inferior alveolar nerve block technique.

Local infiltration technique has been proven as a safer and less painful anesthetic injection technique compared to IANB. Unfortunately, the dense nature of cortical bone in the mandibular posterior region hinders sufficient diffusion of anesthetic solution during infiltration. Thus, to achieve an adequate anesthesia for a painless dental extraction of mandibular posterior teeth by infiltration technique, a strong and effective local anesthetic agent having a deeper penetrating property should be used.

Articaine is one of the most widely used local anesthetic agents. It is more potent and has shown more success rate than Lidocaine and Mepivacaine in providing anesthesia in mandibular and maxillary posterior teeth by buccal infiltration diffusibility.

This study compares the effectiveness of two different volumes of buccal infiltration of Articaine for the extraction of mandibular posterior teeth.

Being tested
1.8 ml of 4% Articaine, 3.6 ml of 4% Articaine
Keywords
Buccal infiltration, Articaine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 1.8 ml of 4% ArticaineOther

    Buccal infiltration of 1.8 ml of 4% Articaine

  • 3.6 ml of 4% ArticaineOther

    Buccal infiltration of 3.6 ml of 4% Articaine.

Study groups in NCT06630819
Study groupRoleWhat they receive
Group AExperimentalBuccal infiltration of 3.6 ml of 4% Articaine
Receives: Other: 3.6 ml of 4% Articaine
Group BActive comparatorBuccal infiltration of 1.8 ml of 4% Articaine
Receives: Other: 1.8 ml of 4% Articaine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intensity of pain

    VAS scale is a validated scale measuring pain with possible score range from 0 (no pain) to 100 (severe pain).

    Measured: From reflection of mucoperiosteum till delivery of tooth out of socket.

  2. Time of onset of anesthesia

    It will be assessed by probing buccal and lingual soft tissue using a dental explorer every 2 minutes after infiltration using a standard digital stop clock.

    Measured: upto 10 minutes

  3. Presence or absence of pain

    A 100 mm Numerical rating scale assessing intraoperative pain. Possible score ranges from 0 (no pain) to 100 (worst possible pain).

    Measured: From reflection of mucoperiosteum till delivery of tooth out of socket.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Oct 2024
  2. Study start24 Nov 2024
  3. Primary completion2 May 2026 (estimated)
  4. Study completion2 May 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
114 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06630819
Sponsor's protocol ID
608/45/14624
Status last verified
May 2025
First submitted
24 Sep 2024
Last updated
29 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A study testing 1.8 ml of 4% Articaine and 3.6 ml of 4% Articaine in people with Buccal Infiltration and Articaine, run by Qassim University at 2 sites in Saudi Arabia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Muhammad Atif S Agwan (966541651713, m.abdulsaleem@qu.edu.sa), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intensity of pain (time frame: From reflection of mucoperiosteum till delivery of tooth out of socket.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in